Carlos Milla, MD, MPH

Assistant Professor, Department of Pediatrics

Director, Cystic Fibrosis Center - Fairview University Medical Center

Background/Education

• Undergraduate: U.P. Cayetano Heredia, Faculty of Sciences and Philo- sophy, Lima, Peru. April 1978 to March 1980.
• Medical School: U.P. Cayetano Heredia, Faculty of Medicine, Lima, Peru April 1980 to March 1986.
• Post-Graduate Work:
  • 1988 to 1989, Clinical Research Fellow at the Instituto de Investigacion Nutricional (Nutrition Research Institute), Lima, Peru.
  • 1993 to 1995, Graduate student at the University of Minnesota School of Public Health, Epidemiology major.
  • 1995 - Doctoral student at the Graduate School of the University of Minnesota, Epidemiology major. (Advisor: Russell V. Luepker, MD, MS)
    
• Residency: Children's Medical Center of Brooklyn, State University of New York Health Sciences Center at Brooklyn. 1989-92
• Fellowship: Pediatric Pulmonology and Cystic Fibrosis, University of Minnesota Hospital and Clinics, 1992-95

Academic Appointments

• Assistant Professor, Pediatrics - University of Minnesota, January 2000-
• Instructor, Department of Pediatrics - University of Minnesota, July 1995-December 1999
• Director Cystic Fibrosis Center - Fairview University Medical Center - 1999-

Clinical Interests

• Bronchoscopy
• Cystic Fibrosis
• Lung Disease in Immunosuppressed patients
• Asthma

Research Interests

• Risk factor assessment and lung function decline in cystic fibrosis. Co-PI with Warren J. Warwick. (Cystic Fibrosis Foundation).
• Doctoral student, Epidemiology major. University of Minnesota School of Public Health. Advisor: Russell V. Luepker.
• Nitric Oxide concentrations in exhaled air as an inflammatory marker in cystic fibrosis.
• P. aeruginosa DNA fingerprinting to determine risk of acquisition in cystic fibrosis. PI: Warren E. Regelmann.
• Multicenter investigation of non-tuberculous Mycobacteria in cystic fibrosis patients. Site PI: Warren J Warwick, Overall PI: Kenneth Oliver. (National Center for Research Resources and Cystic Fibrosis Foundation).
• Use of Cyclosporine A as a corticosteroid-sparing drug in cystic fibrosis patients who are corticosteroid-dependent. PI: Warren J Warwick. (National Center for Research Resources).
• Development of rapid measures of Mycobacterial survival. PI: Warren E. Regelmann. (University of Minnesota Children's Foundation).
• Safety and efficacy of Tobramycin for inhalation in patients with cystic fibrosis. Site PI: Warren E. Regelmann, Overall PI: Bonnie W. Ramsey. (Pathogenesis Corp.).
• Evaluation of the efficacy, safety, tolerance and pharmacokinetics of Meropenem for the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Site PI: Warren J. Warwick, Overall PI: Jeffrey L. Blumer (Center for Drug Research, Rainbow Babies and Children's Hospital, and Zeneca Pharmaceuticals).
• A multicenter, international, randomized, placebo-controlled, double-blind study to determine the effect of Pulmozyme® on pulmonary function over 96 weeks in subjects with cystic fibrosis aged 6 - 10 years. Site PI: Warren E. Regelmann (Genentech, Inc.).

Certification

• Educational Commission for Foreign Medical Graduates, 1989.
• American Board of Pediatrics, 1992.
• American Board of Pediatrics, Pulmonology sub-Specialty Board, 1996.

 Last updated 1/12/2000 at 1605 CST

Publications